Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 40365. Отображено 100.
12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1
Автор: Anton Mayr, Barbara Mayr
Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее
12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1
Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее
19-01-2012 дата публикации

Avirulent, immunogenic flavivirus chimeras

Номер: US20120014981A1

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Подробнее
16-02-2012 дата публикации

Methods and systems for reducing viral load of hepatitis c virus in hemodialysis patients

Номер: US20120037564A1
Принадлежит: Aethlon Medical Inc

The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load.

Подробнее
16-02-2012 дата публикации

Compositions and methods for vaccine and virus production

Номер: US20120039939A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.

Подробнее
16-02-2012 дата публикации

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

Номер: US20120040010A1
Принадлежит: Individual

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Подробнее
15-03-2012 дата публикации

Rtef-1 variants and uses thereof

Номер: US20120063994A1

Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.

Подробнее
22-03-2012 дата публикации

Compositions and methods for identifying enzyme and transport protein inhibitors

Номер: US20120071344A1
Автор: Roland Wolkowicz

The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Подробнее
29-03-2012 дата публикации

Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines

Номер: US20120077249A1
Принадлежит: Millipore Corp

A method of purifying biomolecules with an anion exchanger containing a membrane having a surface having a polymer such as a primary or secondary amine ligand formed thereon, such as polyallylamine. The feedstock is introduced to the exchanger in the presence of one or more ionic-modifiers by themselves or in combination with monovalent salt. The ionic modifier alters the binding ability of the primary amines such that they retain a significant binding capacity for highly charged species such as DNA but lose part or almost all of their binding capacity for less charged species such as viruses or proteins at pH above the pI of the virus or protein.

Подробнее
29-03-2012 дата публикации

Animal-free cell culture method

Номер: US20120077268A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells.

Подробнее
29-03-2012 дата публикации

Materials and Methods for the Treatment of Pathological Neovascularization in the Eye

Номер: US20120077870A1

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

Подробнее
19-04-2012 дата публикации

Process for producing poxviruses and poxvirus compositions

Номер: US20120093780A1
Принадлежит: TRANSGENE SA

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.

Подробнее
19-04-2012 дата публикации

RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF

Номер: US20120093855A1
Автор: Joel R. Haynes
Принадлежит: Ligocyte Pharmaceuticals Inc

The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.

Подробнее
03-05-2012 дата публикации

Composition useful as rotavirus vaccine and a method therefor

Номер: US20120107356A1
Принадлежит: Bharat Biotech International Ltd

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.

Подробнее
03-05-2012 дата публикации

Novel divergent picornavirus: cosavirus

Номер: US20120107357A1
Принадлежит: BLOOD SYSTEMS Inc

Presented herein is the discovery of a new human picornavirus, Cosavirus (previously termed Dekavirus), methods of detecting the Cosavirus and diagnosing Cosavirus infection, methods of treating or preventing Cosavirus infection, and methods for identifying anti-Cosavirus compounds.

Подробнее
10-05-2012 дата публикации

Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof

Номер: US20120114742A1
Принадлежит: Mountain View Pharmaceuticals Inc

Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.

Подробнее
17-05-2012 дата публикации

Tat-Based Vaccine Compositions and Methods of Making and Using Same

Номер: US20120121636A1
Автор: David I. Cohen
Принадлежит: NANIRX Inc

A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based vaccine composition comprising immunostimulatory lentivirus Tat is provided.

Подробнее
17-05-2012 дата публикации

Method to enhance an immune response of nucleic acid vaccination

Номер: US20120121690A1
Принадлежит: Lipoxen Technologies Ltd

A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.

Подробнее
31-05-2012 дата публикации

Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus

Номер: US20120134964A1
Принадлежит: New York University NYU

The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. This involves co-administering a replicating virus and a matrix metalloproteinase to the tumor mass under conditions effective to enhance the delivery to and distribution within the tumor mass of therapeutic viruses. Another aspect relates to a cancer therapeutic. This involves a replicating virus and a matrix metalloproteinase.

Подробнее
07-06-2012 дата публикации

Treatment of Melanoma Using HSV Mutant

Номер: US20120141418A1

Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (R L ) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.

Подробнее
21-06-2012 дата публикации

Novel bacteriophage and antibacterial composition comprising the same

Номер: US20120156174A1
Принадлежит: CJ CHEILJEDANG CORP

The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum and Salmonella pullorum , a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella enteritidis or Salmonella typhimurium , Fowl typhoid caused by Salmonella gallinarum , and Pullorum disease caused by Salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient.

Подробнее
28-06-2012 дата публикации

Chimeric molecules

Номер: US20120164155A1
Автор: Elizabeth Grgacic

The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal α-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp 120. Soluble and membrane bound forms of trimeric and higher oligomeric forms of the chimeric proteins are provided as well as nucleic acid molecules encoding and expressing same, viral-like particles comprising same, compositions including pharmaceutical compositions, host cells and kits. Methods are described for producing immune responses including antibodies determined by the chimeric protein or VLP, as well as methods of screening using the chimeric protein, VLP and/or antibodies.

Подробнее
05-07-2012 дата публикации

Reagents and methods for modulating cone photoreceptor activity

Номер: US20120172419A1

The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.

Подробнее
19-07-2012 дата публикации

Continuous culture apparatus with mobile vessel, allowing selection of fitter cell variants and producing a culture in a continuous manner

Номер: US20120184009A1
Принадлежит: Individual

A method and device for growing plant, animal or stem cells in a continuous manner.

Подробнее
26-07-2012 дата публикации

Attenuated pestiviruses

Номер: US20120189659A1
Автор: Gregor Meyers
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E RNS is inactivated, as well as methods of preparing, using and detecting these pestiviruses.

Подробнее
02-08-2012 дата публикации

Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines

Номер: US20120195937A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.

Подробнее
06-09-2012 дата публикации

Methods of propagating monkey adenoviral vectors

Номер: US20120225470A1
Принадлежит: Genvec Inc

The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.

Подробнее
20-09-2012 дата публикации

Production of viral vaccines in suspension on avian embryonic derived stem cell lines

Номер: US20120238001A1
Принадлежит: Vivalis SA

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Подробнее
27-09-2012 дата публикации

Microorganisms for imaging and/or treatment of tumors

Номер: US20120244068A1
Принадлежит: Individual

Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.

Подробнее
27-09-2012 дата публикации

Adenovirus Infection In Animals

Номер: US20120244187A1
Автор: Richard L. Atkinson
Принадлежит: Obetech LLC

Animals have tested positive for unsuspected natural infection with lipogenic adenoviruses. Methods for testing animals, including food stuffs and experimental animals, for lipogenic adenovirus infection are disclosed. Exposure to infected meat and animal co-products may cause health and safety issues. As a result of lipogenic adenovirus infection in experimental animal species, research related to fat or glucose metabolism, energy metabolism, cancer biology, and obesity research may have been or may be negatively affected or compromised.

Подробнее
18-10-2012 дата публикации

Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer

Номер: US20120263677A1
Принадлежит: PFIZER INC, Provectus Biopharmaceuticals Inc

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.

Подробнее
25-10-2012 дата публикации

Adjuvated Influenza Vaccine and Use Thereof

Номер: US20120269852A1
Принадлежит: Abbott Biologicals BV

A viral vaccine, specifically an influenza vaccine, comprises a combination of a component (a1) represented by a detoxified or non-toxic mutant of subunit A of an AB type exotoxin, and a component (a2) represented by at least one substance selected from the group consisting of metal salts and mineral salts, in association with a viral immunogen.

Подробнее
25-10-2012 дата публикации

Reverse genetics systems

Номер: US20120270321A1
Принадлежит: NOVARTIS AG

The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.

Подробнее
08-11-2012 дата публикации

Functional mutation in respiratory syncytial virus

Номер: US20120282673A1
Автор: Bin Lu, HONG Jin, Robert Brazas
Принадлежит: MEDIMMUNE LLC

The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.

Подробнее
29-11-2012 дата публикации

Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use

Номер: US20120301499A1
Принадлежит: Cytos Biotechnology AG

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

Подробнее
29-11-2012 дата публикации

Method of using adenoviral vectors to induce an immune response

Номер: US20120302627A1

The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.

Подробнее
29-11-2012 дата публикации

Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof

Номер: US20120304321A1
Принадлежит: CELLECTIS SA

A monomer of an I-CreI meganuclease variant wherein said monomer when in dimeric form binds and cleaves DNA.

Подробнее
13-12-2012 дата публикации

METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS

Номер: US20120315696A1
Принадлежит: Crucell Holand BV

Described are methods for large-scale production of recombinant adenovirus 26, utilizing perfusion systems and infection at very high cell densities.

Подробнее
27-12-2012 дата публикации

Compositions and methods for vaccinating against hsv-2

Номер: US20120328656A1
Принадлежит: UNIVERSITY OF WASHINGTON, Vical Inc

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

Подробнее
27-12-2012 дата публикации

Methods and compositions for the production of recombinant virus vectors

Номер: US20120329136A1
Автор: Weidong Xiao
Принадлежит: Individual

A method for the production of a replication-deficient recombinant virus vector is disclosed. The replication-deficient recombinant virus vector has a recombinant virus genome with one or more defective viral genes. The method comprises infecting a host cell with a carrier virus having a carrier virus genome encoding one or more trans factors or variants thereof, incubating the infected host cell for a desired period of time, and isolating the replication-deficient recombinant virus vector. The carrier virus is a cytoplasmic virus that retains the carrier virus genome in the cytoplasm of the host cell. The host cell contains the recombinant viral genome and retains the recombinant viral genome in a nucleus of the host cell. Also disclosed is a carrier virus for the production of a replication-deficient recombinant virus vector.

Подробнее
27-12-2012 дата публикации

Pathogen Restriction Factors

Номер: US20120331576A1

The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein

Подробнее
03-01-2013 дата публикации

Process for manufacturing vaccines

Номер: US20130004532A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.

Подробнее
24-01-2013 дата публикации

Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same

Номер: US20130022574A1
Принадлежит: CJ CHEILJEDANG CORP

The present invention relates to avirulent Salmonella Gallinarum variants by inactivating virulence gene clusters of Salmonella Gallinarum (SG), a main pathogen of avian salmonellosis, and various uses thereof notably in the production of Salmonella -specific lytic bacteriophages, pharmaceutical compositions and feed additives.

Подробнее
07-02-2013 дата публикации

Reverse genetics methods for virus rescue

Номер: US20130034582A1
Принадлежит: NOVARTIS AG

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.

Подробнее
07-02-2013 дата публикации

Compositions, methods and uses for expression of enterobacterium-associated peptides

Номер: US20130034583A1
Принадлежит: Inviragen Inc

Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.

Подробнее
14-02-2013 дата публикации

Hbv drug resistance methods

Номер: US20130040284A1
Принадлежит: Innogenetics NV SA

New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD→YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.

Подробнее
28-02-2013 дата публикации

Preparation method of virus expressing alpha-galactose epitope and vaccine

Номер: US20130052219A1

A method for producing an α-Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an α-Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an α-galactose epitope (Galα1-3Galβ1-4GlcNAc-R: α-Gal hereinafter)-expressing virus, which comprises the steps of: (1) introducing an α1,3- galactosyltransferase gene in an expressible condition into a cell line that does not express α-Gal to obtain a cell line capable of expressing α-Gal; (2) inoculating a virus into the cell line capable of expressing α-Gal to obtain a cell line infected with a virus; and (3) culturing the cell line infected with the virus to obtain a virus expressing α-Gal from the culture medium..

Подробнее
28-02-2013 дата публикации

Jfh-1 based hcv cell culture systems for ns5a of genotypes 1-7

Номер: US20130052716A1
Принадлежит: HVIDOVRE HOSPITAL, KOBENHAVNS UNIVERSITET

The present inventors developed hepatitis C virus recombinants expressing NS5A from genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a or 7a in the context of a genotype 2a backbone. Additional recombinants express NS5A and the structural proteins (Core, E1 and E2), p7 and NS2 from genotype 1a, 1b, 3a, 4a, 5a, 6a or 7a in the genotype 2a backbone. Sequence analysis of the recombinants recovered after viral passage in Huh7.5 cells revealed adaptive mutations in NS5A and/or NS3. The importance of these mutations for improved growth kinetics was shown in reverse genetic studies.

Подробнее
07-03-2013 дата публикации

Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same

Номер: US20130059289A1
Принадлежит: University of Pennsylvania Penn

The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.

Подробнее
21-03-2013 дата публикации

Recombinant Herpes Virus and Pharmaceutical Composition Containing The Same

Номер: US20130071355A1
Принадлежит:

An object of the present invention is to provide a highly-safe recombinant herpes virus showing high antitumor activity regardless of the kind, grade of malignancy, or growth rate of tumor cells. 1. A recombinant herpes simplex virus in which the endogenous ICP6 gene is deleted or inactivated and comprising , on the genome of the virus , an expression cassette constructed to express an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter.2. The recombinant herpes simplex virus according to claim 1 , wherein the endogenous ICP6 gene has been inactivated by inserting the expression cassette in the endogenous ICP6 gene.3. The recombinant herpes simplex virus according to claim 1 , wherein the expression cassette has been inserted into a deletion site of the endogenous ICP6 gene.4. The recombinant herpes simplex virus according to claim 1 , wherein the expression cassette has been inserted in a direction opposite to the direction of the endogenous ICP6 gene.5. A recombinant herpes simplex virus comprising an endogenous ICP6 gene functionally linked to a tumor-specific promoter or tissue-specific promoter.6. The recombinant herpes simplex virus according to claim 1 , wherein the tumor-specific promoter or tissue-specific promoter is a promoter selected from the group consisting of a human telomerase reverse transcriptase (hTERT) promoter claim 1 , a PSES promoter claim 1 , and an osteocalcin (OC) promoter;7. The recombinant herpes simplex virus according to claim 1 , wherein a γ34.5 gene and/or an ICP47 gene is also deleted or inactivated.8. A pharmaceutical composition comprising the recombinant herpes simplex virus as claimed in as an active ingredient.9. The pharmaceutical composition according to claim 8 , which is a therapeutic agent for a tumor.10. The pharmaceutical composition according to claim 9 , wherein the tumor is a tumor selected from the group consisting of tumors with a low growth rate claim 9 , benign tumors claim 9 , and ...

Подробнее
21-03-2013 дата публикации

Bunyavirus vaccine

Номер: US20130071429A1
Принадлежит: University of St Andrews

The present invention provides attenuated viruses for use as vaccines and for the treatment and/or prevention of viral diseases and/or infections.

Подробнее
21-03-2013 дата публикации

MICRORNA-CONTROLLED RECOMBINANT VACCINIA VIRUS AND USE THEREOF

Номер: US20130071430A1
Принадлежит: THE UNIVERSITY OF TOKYO

It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention provides a microRNA-controlled vaccinia virus, in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3′ untranslated region of B5R gene associated with viral proliferation in a vaccinia virus, wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that destroys the cancer cell. 1. A microRNA-controlled vaccinia virus , in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3′ untranslated region of B5R gene associated with viral proliferation in a vaccinia virus , wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that specifically destroys the cancer cell.2. The microRNA-controlled vaccinia virus according to claim 1 , wherein the microRNA expressed in the normal cell represses the expression of the B5R gene to reduce the proliferative capacity of the microRNA-controlled vaccinia virus in the normal cell.3. The microRNA-controlled vaccinia virus according to or claim 1 , wherein the B5R gene into which the microRNA target sequence is inserted in its 3′ untranslated region is introduced into an attenuated vaccinia virus lacking a portion or the whole of its B5R gene.4. The microRNA-controlled vaccinia virus according to or claim 1 , wherein the vaccinia virus is an LC16 strain or an LC16mO strain.5. The microRNA-controlled vaccinia virus according to claim 3 , wherein the vaccinia virus is an LC16m8 strain lacking a portion of its B5R gene or an m8Δ strain lacking the whole of its B5R gene.6. The microRNA-controlled vaccinia virus according to claim 1 , wherein the microRNA less expressed in a cancer cell than in a normal cell ...

Подробнее
28-03-2013 дата публикации

ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION

Номер: US20130078261A1
Принадлежит: Baxter Healthcare S.A.

The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. 1. A preparation comprising purified Ross River Virus antigen being free of contaminating protein from the cells or the cell culture and has less than 10 pg cellular nucleic acid/μg virus antigen.2. The preparation according to claim 1 , further comprising a physiologically acceptable carrier.3. The preparation according to claim 1 , further comprising an adjuvant.4. A vaccine against Ross River Virus infection comprising a host protective amount of a purified Ross River Virus antigen claim 1 , wherein said vaccine is substantially free of any contaminating protein from the cells or the cell culture and has an amount of cellular nucleic acid per vaccine dose of less than 10 pg/μg antigen.5. The vaccine according to claim 4 , wherein said host protective amount of Ross River Virus antigen is between about 0.1 and about 50 μg/dose.6. The vaccine according to claim 4 , further comprising an adjuvant.7. A method of immunizing a mammal against Ross River Virus infection comprising the steps of providing a vaccine comprising a host protective amount of Ross River Virus antigen claim 4 , wherein said vaccine is substantially free of any contaminating protein from the cells or the cell culture and has an amount of cellular DNA of less than about 10 pg/μg antigen claim 4 , and administering said vaccine to a mammal.8. A method for the preparation of an immune globulin preparation specific against Ross River Virus comprising the steps of (i) immunizing a mammal with a vaccine according to and (ii) isolating from the serum of the immunized mammal the immune globulin fraction comprising the RRV specific antibodies. This application is a continuation of U.S. application Ser. No. 11/657,848, filed Jan. 24, 2007 which is a division of U.S. patent ...

Подробнее
28-03-2013 дата публикации

Infectious hepatitis c virus-high producing hcv variants and use thereof

Номер: US20130078277A1

An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing.

Подробнее
04-04-2013 дата публикации

PROCESS FOR PRODUCING POXVIRUSES AND POXVIRUS COMPOSITIONS

Номер: US20130084620A1
Принадлежит: TRANSGENE S.A.

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament. 1. A process for purifying a poxvirus composition from cell culture supernatant and cultured packaging cells infected with a wild type , an attenuated , and/or a recombinant poxvirus with no targeted infection specificity , comprising the steps of:a) recovering poxviral particles from the cell culture supernatant and from cultured packaging cells disrupted by high speed homogenizer, to obtain a poxviral particle mixture,b) clarifying said poxviral particle mixture, thereby removing cellular debris, wherein said clarifying comprises depth filtration, to obtain a clarified poxviral particle mixture,c) concentrating said clarified poxviral particle mixture, wherein said concentrating comprises microfiltration, to obtain a concentrated poxviral particle mixture, andd) diafiltrating said concentrated poxviral mixture to obtain a composition of a wild type, an attenuated, and/or a recombinant poxvirus with no targeted infection specificitywherein said process is free from animal products and does not use nuclease, andwherein said poxvirus composition comprises intracellular mature virus (“IMV”) and extracellular enveloped virus (“EEV”) with more than 1% EEV.2. The process of claim 1 , wherein said poxvirus composition comprises more than 5% EEV.3. The process of or claim 1 , wherein said process for producing said poxvirus composition further comprises step g) of tangential filtration.4. The process of wherein said packaging cell is chicken embryo fibroblast (CEF) prepared by digestion of embryo tissues with trypsin and dispase.5. The process of claim 1 , wherein said poxvirus poxvirux ...

Подробнее
11-04-2013 дата публикации

DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS

Номер: US20130089567A1

The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus. 1. A nucleic acid encoding a dengue virus or chimeric dengue virus comprising a mutation in the 3′untranslated region (3′-UTR) selected from the group consisting of:(a) a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4; and(b) a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR.2. The nucleic acid encoding a dengue virus or chimeric dengue virus of wherein the mutation is (a).3. The nucleic acid encoding a dengue virus or chimeric dengue virus of wherein the mutation removes the TL-2 homologous structure and removes sequence up to and including the TL-3 homologous structure in a contiguous manner contiguous to the Δ30 mutation.4. The nucleic acid encoding a dengue virus ...

Подробнее
11-04-2013 дата публикации

Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions

Номер: US20130089913A1
Принадлежит: Bavarian Nordic AS

The present invention relates to a method for the cultivation of primary cells. The primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The method for the cultivation of primary cells may be one step in a method for the amplification of viruses, such as poxviruses. According to this latter method the primary cells are cultivated in a serum free medium comprising a factor selected from the group consisting of growth factors and attachment factors. The cells are then infected with the virus and the infected cells are cultivated in serum free medium until progeny virus is produced.

Подробнее
18-04-2013 дата публикации

PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN CELL CULTURE

Номер: US20130095135A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS S.A.

The present invention relates to improved processes for the production of viruses, in particular, viruses for use in medicine (for example vaccination or gene therapy). 1. A process for producing a virus of interest in cell culture , comprising contacting a population of cells with a solution comprising the virus of interest , wherein the cells are susceptible to infection with the virus of interest , characterised in that the contact time between the solution comprising the virus of interest and susceptible cells is inferior than or equal to 120 minutes.2. A process for producing a virus of interest comprising the steps of:a) contacting a population of cells with a solution comprising the virus of interest for a period inferior than or equal to about 120 minutes, wherein the cells are susceptible to infection with the virus of interest;b) removing the solution comprising the virus of interest from the cells, andc) incubating the cells in a culture medium to produce a population of replicated virus of interest.3. The process of further comprising the steps step of:d) formulating the produced virus with a suitable pharmaceutical carrier4. The process according to claim 1 , wherein the solution comprising the virus of interest comprises one or more adventitious agents.5. The process according to claim 4 , wherein the cells are susceptible to infection with one or more of the adventitious agents.7. The process of wherein the at least one adventitious agent is removed or substantially removed from the population of replicated virus of interest as compared to the initial solution comprising the virus of interest and the at least one adventitious agent.8. The process according to claim 6 , wherein the contact period of time is inferior than or equal to 120 minutes.9. (canceled)10. The process according to claim 6 , wherein the contact time in step a) is sufficient to permit adsorption of the virus of interest to at least a subset of the population of cells.11. (canceled) ...

Подробнее
18-04-2013 дата публикации

NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM

Номер: US20130095556A1
Принадлежит: International AIDS Vaccine Initiative

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. 1. A vesicular stomatitis virus (VSV) genomic clone comprising:(a) a VSV genome encoding and expressing a nucleocapsid, phosphoprotein, matrix, glycoprotein and large protein, wherein the VSV genome comprises nucleotide substitutions and amino acid coding changes to improve replicative fitness and genetic stability,(b) a cloning vector,(c) an extended T7 promoter,(d) a hammerhead ribozyme,(e) a hepatitis delta virus ribozyme and T7 terminator(f) unique restriction endonuclease cleavage sites in a VSV genomic sequence(g) a leader and a trailer that are cis-acting sequences controlling mRNA synthesis and replication2. The VSV genomic clone of claim 1 , wherein the cloning vector is pSP72 (Genbank X65332.2)3. The VSV genomic clone of claim 1 , wherein the extended T7 promoter is PT7-g10.4. The VSV genomic clone of claim 1 , wherein the unique restriction endonuclease cleavage sites are 1367 NheI claim 1 , 2194 SpeI claim 1 , 2194 BstBI claim 1 , 4687 PacI claim 1 , 7532 AvaI claim 1 , 10190 SalI and 11164 AflII.5. The VSV genomic clone of claim 1 , wherein the VSV genomic clone is depicted in .6. The VSV genomic clone of claim 1 , wherein the nucleotide position is according to GenBank Accession Number EF197793 and wherein the nucleotide substitutions are selected from the group consisting of1371 CA>GC (NheI)After 2195 insert TAG (SpeI) (all genome numbers below adjusted to include +3 bp)3036 G>T improves match to consensus transcription stop signal3853 X>A (was an ambiguity in Genbank file)4691 T>A to generate PacI7546 C>A silent change in L coding sequence eliminates a BstBI site1960 TAC>TCC to change Y>S3247 GTA>ATA to change V>I3729 AAG>GAG to change K>E4191 GTA>GAA to change V>E4386 GGT>GAT to change G>D4491 ACC ...

Подробнее
18-04-2013 дата публикации

PROCESS FOR PRODUCING RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS

Номер: US20130095558A1
Автор: Huang Wenlin
Принадлежит:

This invention discloses a production process for recombinant human endostatin adenovirus in order to optimize the procedure for small batch and mass industrialization. Exemplary process include steps of: (1) fermentation of eukaryotic cells (HEK293 cells) in the condition of 37° C. and 5% CO; (2) adenovirus infection; (3) collection of diseased cells; (4) freezing and thawing; (5) concentration by ultrafiltration; and (6) preparation and packaging of recombinant human endostatin adenovirus. The process is controllable and easy to operate. The concentration of adenovirus titers can reach 1.0×10−3.0×10vp/ml. 1. A process for producing recombinant human endostatin adenovirus useful for injective administration , the process comprising:fermenting eukaryotic cells in a culture;performing adenovirus infection of the eukaryotic cells to yield diseased eukaryotic cells having recombinant human endostatin adenovirus;harvesting the diseased eukaryotic cells;causing cell lyses of the diseased eukaryotic cells; andpurifying the resulting recombinant human endostatin adenovirus.2. The process of claim 1 , wherein the eukaryotic cells are Human Embryonic Kidney 293 (HEK293) cells.3. The process of claim 2 , wherein fermenting eukaryotic cells is carried out in a DMEM medium comprising glucose at a concentration greater than about 1 g/L claim 2 , fetal bovine serum concentration from about 8% to about 12% claim 2 , and an adenovirus culture medium with about 4% to about 6% serum.4. The process of claim 1 , wherein fermenting is carried out in a NBS bioreactor for cell culture.5. The process of claim 2 , wherein fermenting eukaryotic cells is performed under conditions comprising: at a cell density from about 2×10mL to about 5×10/mL claim 2 , at a temperature from about 36° C. to about 37° C. claim 2 , with a COconcentration of about 5% claim 2 , with a pH in the range from about 7.2 to about 7.4 claim 2 , with an oxygen concentration of about 30% to about 70% claim 2 , and at a ...

Подробнее
25-04-2013 дата публикации

Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Номер: US20130101619A1
Принадлежит: Intervet Inc

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

Подробнее
25-04-2013 дата публикации

Recombinant varicella-zoster virus

Номер: US20130101620A1

A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

Подробнее
25-04-2013 дата публикации

In Vitro Method for obtaining Intrahepatic Fibroblasts Infected with Hepatitis C Virus

Номер: US20130101986A1

The present invention relates to in vitro methods for obtaining intrahepatic fibroblasts infected with hepatitis C virus, to the infected intrahepatic fibroblasts obtained by means of these methods, and also to methods for screening for anti-fibrogenesis molecules and for anti-HCV molecules using these cells.

Подробнее
25-04-2013 дата публикации

Method of retrovirus storage

Номер: US20130102048A1
Принадлежит: Takara Bio Inc

A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon.

Подробнее
25-04-2013 дата публикации

Multi Plasmid System For The Production Of Influenza Virus

Номер: US20130102053A1
Автор: Jin Hong, Lu Bin
Принадлежит: MEDIMMUNE, LLC

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. 1. A method of increasing replication of a reassortant influenza A virus by at least 10% , comprising:a) introducing an amino acid substitution to an HA amino acid sequence of the reassortant virus, thereby producing an altered reassortant virus, wherein the amino acid substitution is to threonine at position 196; andb) growing the altered reassortant virus in eggs.2. The method of claim 1 , wherein step a) comprises introducing a second amino acid substitution to the HA amino acid sequence of the reassortant virus claim 1 , wherein the second amino acid substitution is to valine at position 186.3. The method of claim 1 , wherein step a) comprises introducing a second amino acid substitution to the HA amino acid sequence of the reassortant virus claim 1 , wherein the second amino acid substitution is to isoleucine at position 226.4. The method of claim 2 , wherein step a) comprises introducing a third amino acid substitution to the HA amino acid sequence of the reassortant virus claim 2 , wherein the third amino acid substitution is to isoleucine at position 226.5. A replication enhanced reassortant influenza virus produced by the method of .6. A replication enhanced reassortant influenza virus produced by the method of .7. A replication enhanced reassortant influenza virus produced by the method of .8. A replication enhanced reassortant influenza virus produced by the method of .9. The method of claim 1 , wherein the reassortant influenza A virus grows to a titer of at ...

Подробнее
09-05-2013 дата публикации

SWINE INFLUENZA HEMAGGLUTININ VARIANTS

Номер: US20130115235A1
Автор: CHEN Zhongying, Jin Hong
Принадлежит: MEDIMMUNE, LLC

The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. 1. A reassortant influenza virus comprising a first genome segment encoding an isolated or recombinant polypeptide comprising an amino acid sequence selected from the group consisting of:(a) SEQ ID NO:1, or a fragment thereof;(b) a modified SEQ ID NO:1, wherein the amino acid at position 125 is substituted with a non-native amino acid, or a fragment thereof;(c) a modified SEQ ID NO: 1, wherein the amino acid at position 127 is substituted with a non-native amino acid, or a fragment thereof; and(d) a modified SEQ ID NO: 1, wherein the amino acid at position 125 is substituted with a non-native amino acid and the amino acid at position 127 is substituted with a non-native amino acid, or a fragment thereof.2. The reassortant influenza virus of claim 1 , wherein the amino acid sequence comprises amino acids 1-327 of SEQ ID NO:1 or amino acids 1-327 of a modified SEQ ID NO:1 according to (b) claim 1 , (c) or (d).3. The reassortant influenza virus of claim 1 , wherein the first genome segment produces a polynucleotide encoding the polypeptide claim 1 , wherein the polynucleotide comprises a nucleotide sequence of:(i) SEQ ID NO:2, or a fragment thereof, which encodes a polypeptide according to (a), or(ii) a modified SEQ ID NO:2, or a fragment thereof, which encodes a polypeptide according to (b), (c) or (d).4. The reassortant influenza virus of claim 1 , wherein:(i) the amino acid at position 125 of SEQ ID NO:1 is substituted with an aspartic acid (D) or a glutamic acid (E);(ii) the amino acid at position 127 of SEQ ID NO:1 is substituted with a glutamic acid (E); or(iii) the amino acid at position 125 of SEQ ID NO:1 is substituted with an aspartic acid (D) or a glutamic acid (E), and the amino acid at position 127 of SEQ ID NO:1 is ...

Подробнее
09-05-2013 дата публикации

Modified Viral Strains and Method for Improving the Production of Vaccine Seeds of Influenza Virus

Номер: US20130115242A1
Принадлежит:

Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins. 1. A modified influenza A/PR/8/34 virus , whose quantity of HA-NA (hemagglutinin and neuraminidase) glycoproteins on the surface is greater than 550 glycoproteins for a virion of 100 nm in diameter , including a mutated PB 1 gene of SEQ ID NO: 1 coding for a PB1 protein having at least two specific amino acid modifications selected from the group consisting of: 188 (K→E) , 205 (M→I) , 212 (L→V) , 216 (S→G) , 398 (E→D) , 486 (R→K) 563 (I→R) , 576 (I→L) , 581 (E→D) , 584 (R→Q) , 586 (K→R) , 617 (D→N) , 621 (Q→R) , 682 (V→I) and 691 (R→K).2. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes a mutated PB1 gene of SEQ ID NO: 1 coding for a PB1 protein with at least both amino acid modifications 563 (I→R) and 682 (V→I).3. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes the PB 1 gene of another strain of influenza A virus whose quantity of HA-NA surface glycoproteins is greater than 550 glycoproteins for a virion of 100 nm in diameter.4. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes the PB1 gene of H3N2 influenza virus having the sequence of SEQ ID NO: 2.5. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it is reassortant including the HA and NA genes of another influenza virus.6. The modified influenza A/PR/8/34 virus according to claim 5 , including the HA and NA genes of an influenza virus selected from the viruses having the H3N2 claim 5 , H2N2 claim 5 , H1N2 claim 5 , H5N2 claim 5 , H5N1 claim 5 , H7N7 claim 5 , H9N2 and H3N1 subtypes.7. A method for producing HA-NA vaccine glycoproteins of influenza virus claim 5 , wherein a modified influenza virus according to including the HA and NA genes coding for said HA-NA vaccine ...

Подробнее
09-05-2013 дата публикации

MODIFIED HUMAN HEPATITIS C VIRUS GENOMIC RNA THAT CAN BE AUTONOMOUSLY REPLICATED

Номер: US20130115592A1
Принадлежит:

The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1. 1. A modified hepatitis C virus genomic RNA comprising genomic RNA portions of two or more strains of hepatitis C viruses , which comprises a 5′ untranslated region , a core protein coding sequence , an E1 protein coding sequence , an E2 protein coding sequence , a p7 protein coding sequence , an NS2 protein coding sequence , a partial RNA sequence encoding NS3 , NS4A , NS4B , NS5A , and NS5B proteins of a JFH1 strain shown in SEQ ID NO:1 , and a 3′ untranslated region , wherein said modified hepatitis C virus genomic RNA is autonomously replicated and is capable of producing infectious hepatitis C virus particles in a cultured cell system , wherein the core protein coding sequence , the E1 protein coding sequence , the E2 protein coding sequence , and the p7 protein coding sequence are from the hepatitis C virus strain of genotype 1b , wherein the NS2 protein coding sequence is from the hepatitis C virus strain selected from the group consisting of genotype 1b and genotype 2a , and wherein the 5′ untranslated region and ...

Подробнее
23-05-2013 дата публикации

Modified Rodent Parvovirus Capable of Propagating and Spreading Through Human Gliomas

Номер: US20130129683A1
Принадлежит: Deutsches Krebforschungszentrum

Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described. 1. A rodent parvovirus variant capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells.2. A parvovirus variant capable of propagating and spreading through human tumor cells characterized in that it comprises a deletion of 28 amino acids from position 619 to 646 in the C-terminus of N21/from position 126 to 153 in the middle exon of N82.3. A parvovirus variant capable of propagating and spreading through human tumor cells characterized in that it comprises the following amino acid substitution(s) in VP1/2:(a) H374Y;(b) D391N; and/or(c) D4398.4. A parvovirus variant capable of propagating and spreading through human tumor cells characterized in that it comprises a deletion as characterized in .5. The parvovirus variant of claim 1 , wherein the starting strain is a rat parvovirus.6. The parvovirus variant of which is rat H1-PV.7. The parvovirus variant of claim 1 , wherein the tumor cells are glioma cells.8. The parvovorius variant of claim 7 , wherein the glioma is a glioblastoma.9. The parvovirus variant of claim 1 , wherein the semipermissive human tumor cells are NCH149 cells.10. The parvovirus variant of claim 1 , wherein the serial passaging comprises at least 10 passages.11. The parvovirus variant according to claim 1 , wherein ...

Подробнее
23-05-2013 дата публикации

Method and system of particle-phage epitope complex

Номер: US20130130355A1
Принадлежит: Armune Biosciences Inc

The present disclosure provides compositions and methods for using phage epitopes to profile the immune response. The phage epitopes can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for detecting a cancer based on the detection of one or more antibodies. In one embodiment, the antibody is an autoantibody. The present disclosure also provides methods of producing antibody detecting complexes.

Подробнее
30-05-2013 дата публикации

Immunostimulating Polyphosphazene Compounds

Номер: US20130136758A1
Принадлежит: Individual

Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed.

Подробнее
30-05-2013 дата публикации

Biomatrix Scaffolds for Industrial Scale Dispersal

Номер: US20130137176A1

The present invention provides biomatrix scaffolds for industrial scale dispersal.

Подробнее
06-06-2013 дата публикации

Novel modified live-attenuated vaccines (mlv) created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)

Номер: US20130142824A1

The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques. Particularly, the present invention provides infectious chimeric viruses generated by DNA shuffling of the GP5 genes of genetically distinct strains of PRRSV; modified live-attenuated vaccines comprise infectious chimeric viruses containing the shuffled GP5 genes and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins); broadly -protective subunit vaccines comprising PRRSV chimeric shuffled GP5 protein and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins).

Подробнее
06-06-2013 дата публикации

Bionanomaterials and Their Synthesis

Номер: US20130143303A1
Автор: Niu Zhongwei, WANG Qian
Принадлежит: UNIVERSITY OF SOUTH CAROLINA

The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed. 1. A 1-dimensional composite nanofiber comprising:a plurality of functionalized rod-like viruses, wherein each functionalized rod-like virus defines a head and a tail, and wherein the plurality of functionalized rod-like viruses are assembled in a wire-like structure such that the head of one functionalized rod-like virus is adjacent to the tail of an adjacent virus, wherein the functionalized rod-like viruses comprise alkyne-functional rod-like viruses; anda polymer surrounding the wire-like structure to fix the plurality of rod-like viruses together in the wire-like structure.2. The composite nanofiber as in claim 1 , wherein the polymer comprises a plurality of positively charged monomers.3. The composite nanofiber as in claim 1 , wherein the polymer comprises a plurality of monomers having an amino group.4. The composite nanofiber as in claim 1 , wherein the polymer comprises aniline monomers.5. The composite nanofiber as in claim 1 , wherein the polymer comprises polyaniline.6. The composite nanofiber as in claim 1 , wherein the polymer comprises polyaniline claim 1 , polypyrole claim 1 , polythiophene claim 1 , polyethylenedioxythiophene claim 1 , polypyrazole claim 1 , or derivatives or copolymers thereof.7. A two-dimensional nanostructure comprising:a plurality of viruses assembled in a single layer, wherein said plurality of viruses are crosslinked to fix the single layer into the two-dimensional nanostructure.8. A two-dimensional nanostructure as in claim 7 , wherein said plurality of ...

Подробнее
13-06-2013 дата публикации

Organic peroxide compounds for microorganism inactivation

Номер: US20130149194A1
Принадлежит: Individual

Multifunctional organic peroxides are used as microbiological inactivators and/or for degrading nucleic acids. These include at least one carbon atom and at least two organic peroxide groups. The inactivator is ideally a hydroperoxide. The invention is particularly useful during preparation of viral vaccines.

Подробнее
20-06-2013 дата публикации

COMPLEMENTING CELL LINES

Номер: US20130156736A1
Принадлежит:

A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. Also, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, and measles virus. 1. An adenovirus packaging cell line permissive for replication of an E1A/E1B deficient adenovirus vector , wherein said cell line comprises an adenovirus E1A coding sequence and an adenovirus E1B coding sequence each operably linked to a promoter that lacks substantial sequence identity with a native adenovirus E1A or E1B promoter , and wherein said adenovirus E1A coding sequence and said adenovirus E1B coding sequence are stably integrated into said cell line.2. The adenovirus packaging cell line of claim 1 , wherein said adenovirus E1A coding sequence and said adenovirus E1B coding sequence are stably integrated at different sites in said cell line.3. The adenovirus packaging cell line of claim 2 , wherein said packaging cell line is of human origin.4. An adenovirus packaging cell line comprising a first expression vector and a second expression vector stably integrated into the genome ...

Подробнее
20-06-2013 дата публикации

VACCINE COMPRISING BETA-HERPESVIRUS

Номер: US20130156808A1
Автор: JONJIC Stipan
Принадлежит:

The present invention relates to a beta-herpesvirus, preferably a recombinant beta-herpesvirus, wherein the beta-herpesvirus comprises at least one heterologous nucleic acid, wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand. 1. A beta-herpesvirus , preferably a recombinant beta-herpesvirus , wherein the beta-herpesvirus comprises at least one heterologous nucleic acid , wherein the at least one heterologous nucleic acid comprises a gene encoding a cellular ligand.2. The beta-herpesvirus according to claim 1 , wherein the cellular ligand is capable of binding a receptor for the cellular ligand wherein the receptor for the cellular ligand is present on the surface of at least one immune cell claim 1 , and wherein the at least one immune cell is selected from the group consisting of NK cells claim 1 , γδ T cells and activated CD8 T cells.3. The beta-herpesvirus according to claim 1 , wherein the cellular ligand is an NKG2D ligand.4. The beta-herpesvirus according to claim 3 , wherein the NKG2D ligand is a human NKG2D ligand is selected from the group consisting of UL16 binding proteins and MHC class-1-related protein.5. The beta-herpesvirus according to claim 4 , wherein the UL16 binding protein is selected from the group consisting of ULBP2 claim 4 , ULPB1 claim 4 , ULBP3 claim 4 , ULBP4 claim 4 , ULBP5 and ULBP6.6. The beta-herpesvirus according to claim 4 , wherein the MHC class-1-related protein is selected from the group consisting of MICA and MICB.7. The beta-herpesvirus according to claim 1 , wherein the beta-herpesvirus is suitable for inducing an immune response against a beta-herpesvirus claim 1 , wherein the immune response comprises neutralizing antibodies against beta-herpesvirus and/or CD4 T-cells directed against epitopes of beta-herpesvirus and/or CD8 T-cells directed against epitopes of beta-herpesvirus.8. The beta-herpesvirus according to claim 1 , wherein the beta-herpesvirus is human cytomegalovirus.9. ...

Подробнее
20-06-2013 дата публикации

INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS

Номер: US20130156810A1
Принадлежит: MEDIMMUNE, LLC

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. 1. A 6:2 reassortant influenza B virus , wherein said virus comprises 6 internal genome segments from one or more donor viruses and two surface antigen genome segments , wherein the surface antigen genome segments encode an HA and a NA polypeptide , and wherein the HA polypeptide comprises the amino acid sequence of SEQ ID NO: 93.2. The 6:2 reassortant influenza B virus of claim 1 , wherein said one or more donor viruses comprise one or more of the following phenotypes: temperature-sensitive claim 1 , cold-adapted claim 1 , or attenuated.3. The 6:2 reassortant influenza B virus of claim 1 , wherein said one or more donor viruses are selected from the group consisting of B/Ann Arbor/1/66 claim 1 , B/Leningrad/14/17/55 claim 1 , B/14/5/1 claim 1 , B/USSR/60/69 claim 1 , B/Leningrad/179/86 claim 1 , B/Leningrad/14/55 claim 1 , and B/England/2608/76.4. The 6:2 reassortant influenza B virus of claim 1 , wherein said reassortant influenza B virus is killed or inactivated.5. The 6:2 reassortant influenza B virus of claim 1 , wherein said reassortant influenza B virus is a live attenuated reassortant influenza B virus.6. An immunogenic vaccine composition comprising an immunologically effective amount of the reassortant influenza B virus of .7. An immunogenic vaccine composition comprising an immunologically effective amount of the reassortant influenza B virus of .8. An immunogenic vaccine composition comprising an immunologically effective amount of the reassortant influenza B virus of .9. A method for stimulating the immune system of an individual to produce a protective immune response against influenza B virus claim 2 , the method comprising administering to the individual an immunologically effective amount of the reassortant influenza B virus of in a physiologically effective carrier.10. A method for stimulating the immune ...

Подробнее
27-06-2013 дата публикации

Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same

Номер: US20130164262A1
Принадлежит:

Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. 115-. (canceled)16. A method for treating a patient with dyslipoproteinaemia comprising administering to the patient via intravenous injection a recombinant defective adeno-associated virus , wherein the rep gene , the cap gene , or the rep and cap genes of the adeno-associated virus are deleted and replaced by a nucleic acid sequence coding for a biologically active human lipoprotein lipase (LPL) , wherein the nucleic acid sequence is operably linked to a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter , and wherein the nucleic acid sequence is expressed so as to cause a reduction of lipoprotein in the patient.17. A method for treating a patient with hypertriglyceridaemia comprising administering to the patient via intravenous injection a recombinant defective adeno-associated virus , wherein the rep gene , the cap gene , or the rep and cap genes of the adeno-associated virus are deleted and replaced by a nucleic acid sequence coding for a biologically active human lipoprotein lipase (LPL) wherein the nucleic acid sequence is operably linked to a cytomegalovirus (CMV) or Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter , and wherein the nucleic acid sequence is expressed so as to cause a reduction of triglyceride in the patient.18. A method for treating a patient with hypercholesterolaemia comprising administering to the patient via intravenous injection a recombinant defective adeno-associated virus , wherein the rep gene , the cap gene , or the rep and cap genes of the adeno-associated virus are deleted and replaced by a nucleic acid sequence coding for a biologically active human lipoprotein lipase (LPL) , wherein the nucleic ...

Подробнее
27-06-2013 дата публикации

Adenovirus vaccine vectors

Номер: US20130164327A1
Принадлежит: INSTITUT GUSTAVE ROUSSY

The invention relates to recombinant adenovirus displaying one or more heterologous epitope(s) on their fiber protein. These recombinant adenovirus are useful as vaccines for generating an immune response against said epitope(s) in individuals having a pre-existing anti-Ad immunity. 1. A recombinant replication-defective adenovirus having one or more heterologous polypeptide(s) containing one or more target epitope(s) inserted into its fiber protein.2. The recombinant replication-defective adenovirus of claim 1 , further comprising one or more heterologous polypeptide(s) containing the same target epitope(s) inserted into a capsid protein other than the fiber protein.3. A method of generating an immune response against one or more target epitope(s) in a subject having a pre-existing humoral immunity against an adenovirus comprising administering to the subject the recombinant replication-defective adenovirus of .4. A method of generating an immune response against one or more target epitope(s) in a subject comprising administering on a repeating basis to the subject the recombinant replication-defective adenovirus of . The invention relates to adenovirus-based vaccine vectors suitable in particular for administration to individuals presenting a preexisting anti-adenovirus immunity.Adenovirus (Ad)-derived vectors have been largely used in preclinical and clinical studies targeting cancer or genetic diseases. Different studies have also investigated their use as vaccine platform against different antigens (TATSIS & ERTL, Mol Ther, 10, 616-29, 2004). Thus, recombinant Ad were shown to induce strong humoral and cellular responses against infectious pathogens such as Ebola (SULLIVAN et al., PLoS Med, 3, e177, 2006), HIV (SHU et al., Vaccine, 25, 1398-408, 2007), Hepatitis C virus (MARTIN et al., Vaccine, 26, 2471-81, 2008) but also against tumor-associated antigens (WARNIER et al., Int J Cancer, 67, 303-10, 1996). These vectors are relatively easy to construct and can be ...

Подробнее
27-06-2013 дата публикации

CELL-BASED METHODS AND REAGENTS

Номер: US20130164329A1
Принадлежит: ALNYLAM PHARMACEUTICALS, INC.

The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided. 1. A method of isolating a cell that is substantially devoid of a target virus , comprising:a. contacting a population of cells a portion of which comprises the target virus with an RNA effector molecule that inhibits the growth or replication of the target virus;b. detecting the presence of the target virus in each cell; and,c. isolating at least one cell that is substantially devoid of the target virus.2. The method of claim 1 , further comprising repeating steps a-c.3. The method of claim 2 , further comprising detecting the presence or absence of target viral nucleic acid or protein.4. The method of claim 3 , wherein the isolated cell is free of the target virus.5. The method of claim 4 , wherein steps a-c are repeated when target viral nucleic acid or protein is detected.6. The method of claim 5 , wherein the target viral nucleic acid is detected by a method selected from the group consisting of: polymerase chain reaction (PCR) claim 5 , reverse transcription polymerase chain reaction (RT-PCR) claim 5 , rapid amplification of cDNA ends (RACE) claim 5 , dot blot hybridization claim 5 , Northern hybridization claim 5 , and Southern hybridization.7. The method of claim 5 , wherein the target viral protein is detected by a method selected from the group consisting of: radioimmunoassay claim 5 , competitive-binding assay claim 5 , ELISA claim 5 , Western blot claim 5 , FACS claim 5 , immunohistochemistry claim 5 , immunoprecipitation claim 5 , proteomics claim 5 , mass spectrometry claim 5 , electrophoresis claim 5 , and immunofluoresence.8. The method of claim 1 , wherein the presence of the target virus of step b. is immunologically detected.9. The method of claim 8 , ...

Подробнее
27-06-2013 дата публикации

METHOD FOR SEPARATING VIRUSES FROM A CONTAMINANT-CONTAINING LIQUID

Номер: US20130164821A1
Принадлежит: SARTORIUS STEDIM BIOTECH GMBH

The present invention relates to a method for separating viruses from a contaminant-containing liquid medium using two adsorbents having cationic groups, wherein the viruses are adsorbed to the first adsorbent and subsequently eluted and wherein the contaminants present in the resulting eluate are subsequently adsorbed to the second adsorbent. The yield and purity of the viruses obtained as per the method according to the invention is increased by the addition of multivalent anions during the adsorption of the contaminants to the second adsorbent. 1. A method for separating viruses from a contaminant-containing liquid medium , comprising the following steps:A) contacting the liquid medium with a first adsorbent containing cationic groups,B) separating the liquid medium from the first adsorbent,C) desorbing the viruses from the first adsorbent,D) contacting a second adsorbent containing cationic groups with a liquid medium comprising the viruses from step C) and multivalent anions, andE) separating the virus-containing liquid medium from step D) from the second adsorbent.2. The method as claimed in claim 1 , wherein the first adsorbent and the second adsorbent are selected from the group of the chromatography matrices comprising adsorption membranes claim 1 , gels and monoliths.3. The method as claimed in claim 2 , wherein different chromatography matrices are used for the first and the second adsorbent.4. The method as claimed in claim 2 , wherein identical chromatography matrices are used for the first and the second adsorbent.5. The method as claimed in claim 2 , wherein the adsorption membrane is a microporous membrane from a cellulose derivative claim 2 , polyamide claim 2 , poly(ether)sulfone claim 2 , polyvinylidene difluoride claim 2 , polyacrylonitrile claim 2 , polyvinyl chloride claim 2 , polypropene claim 2 , polyethene claim 2 , polytetrafluoroethene claim 2 , copolymers thereof or mixtures thereof.6. The method as claimed in claim 1 , wherein the ...

Подробнее
04-07-2013 дата публикации

Constrained immunogenic compositions and uses therefor

Номер: US20130171129A1
Принадлежит: MONASH UNIVERSITY

A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV), Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.

Подробнее
04-07-2013 дата публикации

Soluble Forms of Hendra and Nipah Virus G Glycoprotein

Номер: US20130171131A1
Принадлежит: Individual

This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.

Подробнее
04-07-2013 дата публикации

FELINE PICORNA VIRUS AND USES THEREOF

Номер: US20130171150A1
Принадлежит:

The invention is directed to a Feline Picorna Virus, an isolated nucleic acid and amino acid sequences therefrom, and uses thereof. 1. An isolated nucleic acid comprising SEQ ID NO: 1.2. (canceled)3. An isolated nucleic acid comprising from 10 to 7490 consecutive nucleotides selected from: SEQ ID NO: 1 , a sequence complementary to SEQ ID NO: 1 , a sequence having about 85% identity to SEQ ID NO: 1 , or a sequence having about 85% identity to a sequence complementary to SEQ ID NO: 1 , wherein the % identity is determined by analysis with a sequence comparison algorithm.4. An isolated nucleic acid comprising a nucleic acid encoding any one of the peptide of SEQ ID NOs: 2-18 , or a conserved variant of any one of the peptide of SEQ ID NO: 2-18 , or a variant thereof.5. (canceled)6. (canceled)74. A replicable vector comprising any one of the nucleic acids of -.8. An isolated peptide comprising any one of the peptides of SEQ ID NOs: 2-18 claims 1 , or a conserved variant of SEQ ID NOs: 2-18.9. (canceled)10. An immunogenic composition comprising FeSV claims 1 , a component of FeSV claims 1 , or a combination thereof.11. The immunogenic composition of claim 10 , wherein the component is a nucleic acid of FeSV or a fragment thereof claim 10 , or a peptide of FeSV claim 10 , or a fragment thereof.12. The immunogenic composition of claim 11 , wherein peptide is P1 claim 11 , VP1 claim 11 , VP2 claim 11 , VP3 claim 11 , VP4 claim 11 , or any combination thereof.13. The immunogenic composition of claim 10 , wherein the FeSV is attenuated claim 10 , inactivated claim 10 , or a combination thereof.14. A pharmaceutical composition for the treatment of a feline picorna virus infection or symptoms thereof claim 10 , comprising an immunogenic composition comprising FeSV claim 10 , an immunogenic composition comprising a component of FeSV claim 10 , an antibody against FeSV claim 10 , an antibody against a component of FeSV claim 10 , or a combination thereof.15. A method to treat ...

Подробнее
04-07-2013 дата публикации

Immunogenic composition

Номер: US20130171188A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 μg.

Подробнее
04-07-2013 дата публикации

Lentiviral vector based immunological compounds against malaria

Номер: US20130171195A1
Принадлежит: Frédéric Philippe COUTANT, Pierre Charneau

The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a Plasmodium parasite capable of infecting a mammalian host. The lentiviral vector particles are used in order to elicit an immunological response against malaria parasites.

Подробнее
04-07-2013 дата публикации

VIRAL VARIANTS AND METHODS FOR DETECTING SAME

Номер: US20130171620A1
Принадлежит: MELBOURNE HEALTH

The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents. 1. An isolated HBV mutant , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV , wherein said mutation(s) result(s) in at least one amino acid addition , substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase and/or in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase and/or in the E domain corresponding to amino acid residues 592-600 of a wild-type HBV polymerase , or in a region proximal thereto.2. An isolated HBV mutant according to claim 1 , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV claim 1 , wherein said mutation(s) result(s) in at least one amino acid addition claim 1 , substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase.3. An isolated HBV mutant according to claim 1 , comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV claim 1 , wherein said mutation(s) result(s) in at least one amino acid addition claim 1 , substitution and/or deletion in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase.4. An isolated HBV mutant according to claim 1 , ...

Подробнее
11-07-2013 дата публикации

PARAPOXVIRUS EXPRESSING THE VP60 MAJOR CAPSID PROTEIN OF THE RABBIT HAEMORRHAGIC DISEASE VIRUS

Номер: US20130177582A1
Автор: Rziha Hanns-Joachim
Принадлежит: RIEMSER ARZNEIMITTEL AG

The invention describes a therapeutic agent capable of treating and/or preventing rabbit haemorrhagic disease virus infection in rabbits, namely a recombinant parapoxvirus, characterized in that the VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV) is expressed from a foreign nucleic acid. 1. A recombinant parapoxvirus comprising VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV).2. The parapoxvirus according to claim 1 , wherein the VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV) is expressed from a foreign nucleic acid sequence.3. The parapoxvirus according to claim 1 , wherein the parapoxvirus is an Orf virus (ORFV) claim 1 , preferably the ORFV-strain D1701 claim 1 , more preferably D1701-V-VP60n.442. The parapoxvirus according to claim claim 1 , wherein the foreign nucleic acid sequence is a DNA sequence integrated into the parapoxvirus genome.5. The parapoxvirus according to claim 1 , wherein the VP60 major capsid protein is encoded by a DNA sequence comprising the sequence according to SEQ ID No. 1 or SEQ ID No. 2.6. The parapoxvirus according to claim 1 , wherein the VP60 major capsid protein comprises the amino acid sequence according to SEQ ID No. 3.78-. (canceled)9. A composition comprising the parapoxvirus according to claim 1 , a nucleic acid molecule encoding the VP60 protein according to SEQ ID No. 1 or SEQ ID No. 2 and/or the VP60 protein comprising the sequence according to SEQ ID No. 3 and a pharmaceutically acceptable carrier.10. (canceled)11. Vaccine comprising the parapoxvirus according to claim 1 , whereby the parapoxvirus is preferably alive.12. The vaccine according to the preceding claim 11 , wherein that additional agents are present for enhanced vaccine function claim 11 , such as adjuvants or immune stimulators.13. The vaccine according to claim 11 , wherein that the vaccine is a combination vaccine claim 11 , comprising of vaccine-agents for additional ...

Подробнее
11-07-2013 дата публикации

Functional influenza virus-like particles (vlps)

Номер: US20130177587A1
Принадлежит: Novavax Inc

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

Подробнее
11-07-2013 дата публикации

System comprising bacteriophages and particles that contain active substances

Номер: US20130178390A1
Принадлежит: BAYER TECHNOLOGY SERVICES GMBH

The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces. The present invention furthermore concerns the use of the system for delayed release of active agents and also a method for production of the system. The present invention furthermore concerns a method for the selection of phage species from a combinatorial phage population.

Подробнее
18-07-2013 дата публикации

Computationally optimized broadly reactive antigens for influenza

Номер: US20130183342A1
Принадлежит: Individual

Described herein is the development of a computationally optimized influenza HA protein that elicits broadly reactive immune response to all H5N1 influenza virus isolates. The optimized HA protein was developed through a series of HA protein alignments, and subsequent generation of consensus sequences, for clade 2 H5N1 influenza virus isolates. The final consensus HA amino acid sequence was reverse translated and optimized for expression in mammalian cells. It is disclosed herein that influenza virus-like particles containing the optimized HA protein are an effective vaccine against H5N1 influenza virus infection in animals.

Подробнее
18-07-2013 дата публикации

NOVEL METHOD FOR GENERATION OF RNA VIRUS

Номер: US20130183740A1

The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus which comprises at least one amino acid modification within the N-terminal cyto plasmic region of the NA protein. 1. A method for production of negative stranded segmented RNA virus particles , comprising the steps of:a) providing a linear expression construct free of any amplification and/or selection sequences, which construct comprises an RNA polymerase I (polI) promoter and a polI termination signal, both inserted between an RNA polymerase II (polII) promoter and a polyadenylation signal, which construct further comprises a HA and/or a NA gene segment inserted between the polI promoter and the polI termination signal,b) transfecting a host cell with said linear expression construct,c) infecting said host cell with a helper virus having helper virus HA and/or NA proteins, wherein said NA protein comprises at least one amino acid modification within the N-terminal cytoplasmic domain,d) cultivating said host cell to propagate virus particles, (i) the HA and/or NA proteins derived from the linear expression construct, but do not comprise', '(ii) the helper virus HA and NA proteins, or segments thereof,, 'e) selecting the virus particles, wherein said virus particles comprisewherein said selection is based on phenotypic, genotypic or antigenic properties of the HA and/or NA proteins.2. A method according to claim 1 , wherein the host cell is transfected with linear constructs encoding a proteins selected from the group consisting of PB1 claim 1 , PB2 claim 1 , PA claim 1 , NS claim 1 , M claim 1 , and NP.3. A method according to claim 1 , wherein progeny virus particles comprising HA protein derived from the helper virus are separated from candidate virus particles by treating progeny virus particles with a protease claim 1 , and wherein the protease does not cleave HA protein derived from the helper virus ...

Подробнее
18-07-2013 дата публикации

METHOD FOR HARVESTING EXPRESSION PRODUCTS

Номер: US20130183742A1
Принадлежит: BAVARIAN NORDIC A/S

The present invention provides a method for recovering an essentially cell-associated expression product from a host cell comprising (a) culturing said host cell under conditions that allow expression of said expression product; (b) collecting said host cell in/on a filter unit; (c) disrupting said host cell in/on the filter unit; and (d) separating said expression product from said disrupted host cell. Said host cell is preferably a vertebrate cell, more preferably an avian cell, which is preferably cultured in suspension. Furthermore, the present invention provides for the use of a filter unit characterized in that said filter unit is (i) suitable to retain a host cell which expresses an expression product; and (ii) suitable for elution of said expression product from the filter unit after cell disruption in/on said filter unit for recovering said expression product from said host cell as well as for a system for recovering an expression product from a host cell comprising said filter unit. The present invention also provides an expression product obtainable by said method, said expression product being preferably a virus, specifically a poxvirus, in particular selected from the group consisting of fowlpoxvirus, vaccinia virus and, more preferably, modified vaccinia virus Ankara, MVA. 121-. (canceled)23. The method of claim 22 , wherein the poxvirus is selected from the group consisting of fowlpox virus claim 22 , vaccinia virus claim 22 , and modified vaccinia virus Ankara (MVA).24. The method of claim 23 , wherein the filter unit is suitable to separate the host cell from cell culture medium.25. The method of claim 23 , wherein the filter unit is suitable to allow passing through of the expression product and/or elution of the expression product from the host cell after cell disruption in or on the filter unit.26. The method of claim 25 , wherein the filter unit is further suitable to allow passing through of a disrupted host cell.27. The method of claim 23 , ...

Подробнее
18-07-2013 дата публикации

Recombinant bacteriophage and methods for their use

Номер: US20130184183A1
Принадлежит: AvidBiotics Corp

Recombinant P4 bacteriophage containing modified tail fibers having a base plate attachment region (BPAR) from a P2 bacteriophage gene H product and a heterologous receptor binding domain (RBD) are disclosed. Methods for the use of the recombinant P4 bacteriophage, such as to detect the presence of a target bacterium in a sample, are also described.

Подробнее
25-07-2013 дата публикации

MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY

Номер: US20130189265A1
Принадлежит: DEUTSCHES KREBSFORSCHUNGSZENTRUM

Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. 1. A parvovirus variant showing higher anti-tumor potential compared to the wild type parvovirus , wherein said variant is characterized by (a) an amino acid substitution , deletion or addition at position Lys96 of NS-2 and/or position Leu103 of NS-2 , or (b) an in-frame deletion in the left-hand part of the parvovirus genome affecting both the central part of NS2 and the C-terminal part of the NS1 protein sequences.2. The parvovirus variant of claim 1 , wherein said variant is characterized by amino acid substitution(s) claim 1 , or said variant is characterized by an in-frame deletion from nt 2022 to 2135 resulting in the translation of an NS1 protein having a deletion of aa 587-624 and an NS2 protein having a deletion of aa 96-133.3. The parvovirus variant of claim 2 , wherein Lys at position 96 of NS-2 is replaced by an hydrophilic polar amino acid and/or Leu at position 103 of NS-2 is replaced by a neutral nonpolar amino acid.4. The parvovirus variant of claim 3 , comprising the following amino acid substitution(s) Lys96Glu and/or Leu103Pro of NS-2.5. The parvovirus variant of claim 4 , comprising the following substitution(s):(a) Lys96Glu of NS2; or(b) Leu103Pro of NS2 and Tyr595His of NS1.6. The parvovirus variant of claim 1 , which is derived from parvovirus H-1 (H-1PV ...

Подробнее
25-07-2013 дата публикации

Flavivirus Vaccines

Номер: US20130189306A1
Автор: Guirakhoo Farshad
Принадлежит: Sanofi Pasteur Biologics, LLC

The invention provides flavivirus vaccines and methods of making and using these vaccines. 1. A chimeric flavivirus comprising sequences encoding capsid and non-structural proteins of a yellow fever virus and pre-membrane and envelope proteins of a dengue virus selected from a dengue-1 virus , a dengue-2 virus , a dengue-3 virus , and a dengue-4 virus , wherein the dengue virus envelope protein has a mutation in amino acid position 202 (dengue-3) or 204 (dengue-1 , dengue-2 , or dengue-4).2. The chimeric flavivirus of claim 1 , wherein said yellow fever virus is a yellow fever virus vaccine strain.3. The chimeric flavivirus of claim 2 , wherein said yellow fever virus vaccine strain is YF17D.4. The chimeric flavivirus of claim 1 , wherein said dengue virus is dengue-1.5. The chimeric flavivirus of claim 1 , wherein said dengue virus is dengue-2.6. The chimeric flavivirus of claim 1 , wherein said dengue virus is dengue-3.7. The chimeric flavivirus of claim 1 , wherein said dengue virus is dengue-4.8. The chimeric flavivirus of claim 1 , wherein the mutation is an attenuating mutation.9. The chimeric flavivirus of claim 1 , wherein the mutation is a substitution of the lysine at position 202 (dengue-3) or 204 (dengue-1 claim 1 , dengue-2 claim 1 , or dengue-4).10. The chimeric flavivirus of claim 9 , wherein said lysine is substituted with arginine.11. An immunogenic composition comprising the flavivirus of and a pharmaceutically acceptable carrier or diluent.12. The immunogenic composition of claim 10 , wherein said composition comprises a chimera of yellow fever virus and dengue-1 virus claim 10 , a chimera of yellow fever virus and dengue-2 virus claim 10 , a chimera of yellow fever virus and dengue-3 virus claim 10 , and a chimers of yellow fever virus and dengue-4 virus.13. A method of inducing an immune response to a flavivirus in a patient claim 11 , said method comprising administering to said patient the immunogenic composition of .14. The method of claim 13 ...

Подробнее
25-07-2013 дата публикации

Multi plasmid system for the production of influenza virus

Номер: US20130189762A1
Принадлежит: MEDIMMUNE LLC

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. In addition, the present invention includes an improved method of rescue, wherein animal cells (e.g., SF Vero cells) are electroporated with plasmids and vectors of the invention.

Подробнее
01-08-2013 дата публикации

H3 equine influenza a virus

Номер: US20130195906A1
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

Подробнее
01-08-2013 дата публикации

Poxvirus Expression System

Номер: US20130195912A1
Принадлежит: Oxford University Innovation Ltd

There is provided a method for inserting a nucleic acid sequence that encodes a foreign peptide into a poxvirus genome, said method comprising: identifying in the poxvirus genome a poxvirus open reading frame wherein said open reading frame is characterised by an initial ATG start codon and wherein expression of said open reading frame is driven by an operably-linked poxvirus promoter located upstream of the open reading frame and wherein expression of said open reading frame provides a peptide that is non-essential to viability of the poxvirus; and inserting the nucleic acid sequence that encodes the foreign peptide at a position downstream of the poxvirus promoter; wherein following said insertion, (i) the nucleic acid that encodes the foreign peptide is operably-linked to the poxvirus promoter and expression of said nucleic acid is driven by said poxvirus promoter; and (ii) translation of the foreign peptide is initiated at an ATG start codon located at the same position as the ATG start codon of the poxvirus open reading frame. Also provided are a poxvirus vector and corresponding uses of the poxvirus vector in medicine.

Подробнее